New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:31 EDTCVMCEL-SCI receives approval to expand Phase III trial to U.K.
CEL-SCI Corporation announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted regulatory approval to begin the company’s Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in the United Kingdom. The U.K. becomes the 13th country to join the trial. Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer. Further expansion of the trial is underway with a goal to have a total of about 100 clinical centers through 20 countries by the end of 2015. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
08:46 EDTCVMCEL-SCI cleared to enroll patients in trial in Belarus
Subscribe for More Information
February 19, 2015
08:06 EDTCVMCEL-SCI says Malaysia approves patient enrollment for Phase 3 Multikine trial
CEL-SCI announced the Ministry of Health Malaysia has cleared the company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine -- Leukocyte Interleukin, Injection -- in Malaysia. Malaysia is the 20th country to approve CEL-SCI’s Phase III trial, which now has over 350 patients enrolled. “Our plan called for having the trial cleared and conducted in a total of 21 countries, the United States plus 20 other countries. We are almost there,” stated CEO Geert Kersten. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use